Document is current
Any future updates will be listed below
-
Authors
Leeman, Jennifer
Rohweder, Catherine L.
Lin, Feng-Chang
Lightfoot, Alexandra F.
Costello, Jennifer Medearis
Farahi, Narges
Harper, Kimberly
Quist-Nelson, Johanna
Teal, E. Nicole
Vu, Maihan B.
Wheeler, Sarahn
Menard, M. Kathryn
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
National Heart, Lung, and Blood Institute (OT2HL158287)
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 11 September 2024
First Online: 30 September 2024
Declarations
:
: The AC<sup>3</sup>HIEVE Clinical Trial was approved by the Office of Human Research Ethics at The University of North Carolina at Chapel Hill, IRB#23–0968, on 8/17/23. All study participants will provide informed consent.
: Not applicable.
: The AC<sup>3</sup>HIEVE clinical trial is sponsored by The University of North Carolina at Chapel Hill.
: The authors declare no competing interests.
